AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01822756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Study NCT01822756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Other names: Gemzar®
Study NCT01822756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Other names: Abraxane®
Study NCT01822756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
Study NCT01006538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epimacular Brachytherapy
Description: Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
Study NCT01006538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
Study NCT00902369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Study NCT03666715 — intervention group
Intervention type: DRUG
Intervention: Oral Antipsychotics (OAPs)
Description: No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
Study NCT03666715 — intervention group
Intervention type: DRUG
Intervention: Paliperidone Palmitate 1-Month Formulation (PP1M)
Description: No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
Study NCT00703989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: benfotiamine, α-lipoic acid
Description: benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
Study NCT01006538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
Study NCT01953133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Counselling Sessions
Description: 4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
Study NCT03398798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .014
Description: .014 CuNiTi orthodontic arch wire
Study NCT03398798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .016
Description: .016 CuNiTi orthodontic arch wire
Study NCT03398798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin brackets
Description: Ormco Insignia Metal Twin brackets
Study NCT03398798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-ligating brackets
Description: Ormco Insignia SL brackets
Study NCT03773549 — intervention group
Intervention type: OTHER
Intervention: Virtual reality experience
Description: Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
Study NCT03492021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention_AP-CPT
Description: Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
Study NCT03492021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention_PP-PPT
Description: Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
Study NCT02233998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Rinse 1
Study NCT02233998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Rinse 2
Study NCT02233998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouth Rinse 3
Study NCT02564536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: -Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
Study NCT02564536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: -From commercial stock
Study NCT01499849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: (4 X 50 mg capsules) 200 mg PO
Study NCT01499849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: 10 mcg/kg IV
Study NCT01499849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 10 mcg/kg IV
Study NCT01499849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: 20 mg PO and 8 mg PO
Study NCT01499849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg PO and 8 mg PO
Study NCT01499849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (4 X 0 mg capsules) 0 mg PO
Study NCT04440800 — intervention group
Intervention type: DEVICE
Intervention: Wearable activity tracker - FitBit
Description: Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
Study NCT03736980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100% lactose
Study NCT02956044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin
Study NCT02956044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 4 mg glimepiride
Study NCT02956044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin
Study NCT03832114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Increasing doses of LNP023 up to 200 mg.
Study NCT02478840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: recombinant human alpha-mannosidase
Study NCT00750191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Transdiscal Radiofrequency Annuloplasty
Description: Adjustment in dosage form, frequency and or duration.
Study NCT00750191 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Transdiscal Radiofrequency Annuloplasty
Description: interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
Study NCT02791191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: Administered orally
Study NCT02791191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT04376047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Description: The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.
Study NCT04376047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-recumbent position
Description: The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
Study NCT03197428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
Study NCT03197428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
Study NCT03010891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The bundle of supportive interventions
Description: usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC > 45 minutes
Study NCT03010891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual NICU care
Description: usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
Study NCT03474900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLGA implant, Bioretec ltd. Finland
Description: The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
Study NCT03474900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium elastic stable nail
Description: Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
Study NCT01373684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 μg per week s.c. for a total duration of 48 weeks.
Study NCT01373684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue
Description: All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
Study NCT03736980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybine
Description: Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
Study NCT02513030 — intervention group
Intervention type: PROCEDURE
Intervention: Defibrillation testing during ICD replacement
Study NCT03696433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-salt diet
Description: The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
Study NCT03696433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-salt diet
Description: The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
Study NCT02072304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based CBT
Description: A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
Study NCT02072304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supportive care
Description: supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
Study NCT03848065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Study NCT03848065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine (PCV13)
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
Study NCT03848065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Description: Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
Study NCT03848065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Description: Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
Study NCT03668392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
Study NCT01890434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
Study NCT01956630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically modified DCs plus CIK cells
Study NCT01956630 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor leukocyte infusions (DLI)
Study NCT02202512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets
Study NCT02202512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Study NCT02202512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 high dose
Description: tablets
Study NCT02202512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 low dose
Description: tablets
Study NCT02202512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Study NCT02202512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958
Description: tablets
Study NCT00522314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV and ACBT
Study NCT04146376 — intervention group
Intervention type: OTHER
Intervention: Use of a postpartum diary and additional blood draws
Description: A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken.
Study NCT04146376 — intervention group
Intervention type: DRUG
Intervention: VWF replacement therapy with Wilate
Description: This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy
Study NCT04146376 — intervention group
Intervention type: DRUG
Intervention: Tranexamic acid
Description: This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
Study NCT04146376 — intervention group
Intervention type: OTHER
Intervention: Use of a postpartum diary and additional blood draws.
Description: A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken.
Study NCT01339338 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: warming the contrast media
Description: warm the contrast media with 37℃ water-bathing
Study NCT00522314 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Cycle of Breathing Techniques
Study NCT06411977 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vegetable juice
Description: Vegetable juice (Fa. Fitrabbit, Voglsam)
Study NCT01608217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta-9-tetrahydrocannabinol (delta-THC)
Description: delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
Study NCT01608217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (tablet) three times daily for a period of three weeks.
Study NCT01608217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg three times daily for a period of 3 weeks
Study NCT01608217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg three times daily for a period of three weeks
Study NCT03207178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixed CD19/CD20 CAR-T Transfer
Description: Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
Study NCT02739529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel
Study NCT06232148 — intervention group
Intervention type: DEVICE
Intervention: Type of surgery
Study NCT03267173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cell
Description: Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
Study NCT05186831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: Patients will be asked to text their BP. They will receive an automated response to their texts.
Study NCT05186831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online patient portal
Description: Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.
Study NCT01753219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Onstep
Study NCT01753219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein
Study NCT01949025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALARM intervention
Description: The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
Study NCT04086537 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hepcidin levels and BMPR2 expression
Description: Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
Study NCT02437305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABCDEs of Melanoma Skin Cancer
Description: Modified melanoma educational intervention that is targeted towards people of color.
Study NCT02437305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABCDEs of Melanoma
Description: Conventional melanoma educational intervention.
Study NCT00145418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin + Docetaxel
Description: Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
Study NCT00675818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous venvenous hemofiltration (CVVH)
Description: Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
Study NCT00675818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous venovenous hemodialysis (CVVHD)
Description: Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
Study NCT00537667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anakinra
Description: anakinra
Study NCT00537667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anakinra and PEG sTNF-R1
Description: anakinra and PEG sTNF-R1
Study NCT02200419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: POC-based transfusion algorithm
Description: A transfusion algorithm based on point-of-care coagulation testing.
Study NCT01470690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boceprevir
Description: Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
Study NCT01470690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Description: Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
Study NCT01470690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg QD for 5 consecutive days
Study NCT01470690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole 40 mg QD for 5 consecutive days
Study NCT00391677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills training with attention shaping procedures
Description: Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
Study NCT01913912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX.
Description: In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine
Study NCT01913912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.